SHINE Secures European Marketing Authorization for Ilumira, Latest Step in Building Integrated Nuclear Medicine Platform

▤ Summary

SHINE secured European marketing authorization for Ilumira, its non-carrier-added lutetium-177 product used in radioligand therapy development. The approval opens access to a major European market and supports SHINE’s broader nuclear medicine strategy. SHINE is pairing this milestone with its expanded diagnostic isotope business to serve hospitals, imaging centers, and radiopharmaceutical developers from a U.S.-based supply platform. The company also highlighted recent fundraising, a facility acquisition, and DOE financing as part of its continued scale-up.

▦ Linked Companies